Supply of ‘Ready-to-Test’ Mice Being Made Available to Alzheimer’s Researchers

Supply of ‘Ready-to-Test’ Mice Being Made Available to Alzheimer’s Researchers
Taconic Biosciences is improving its services to Alzheimer’s disease researchers — creating a ready-to-use stock of an important mouse model of the disease. Earlier procedures forced researchers to wait for months to receive mice ready for experiments, potentially slowing research efforts. As human brains are difficult to study, animal models are often used in Alzheimer’s research. Among them, so-called transgenic mice— engineered to carry specific gene mutations — play a key part. The mice, called APPSWE–Model 1349, produce large amounts of the amyloid precursor protein (APP), which give rise to amyloid-beta. APPSWE is short for what researchers call the Swedish Mutation, and the mutated gene is a known factor in families with an increased risk of Alzheimer’s disease. The model in itself is not new; Taconic has long offered it. But studying a disease linked to aging has its specific restrictions, because young mice do not show abnormalities. When researchers order the mice, they then have to wait for months until the mice became old enough to be relevant —  up to 42 weeks of age. Taconic says it will now have aged animals in stock. “The addition of aged APPSWE animals demonstrates Taconic’s commitment to help researchers reduce discovery timelines. These reductions save both time and money, ultimately making it easier to progress towards life-changing therapeutics,” Dr. Michael Seiler, Taconic Biosciences’ portfolio director for genetically engineered models, said in a press release. The APPSWE–Model 1349 mice show similar brain changes as
Subscribe or to access all post and page content.


  1. Dante J Marciani says:

    While transgenic mice are an important tool in Alzheimer’s research, we should recognize its limitations. For practical purposes, all of the drugs that showed pre-clinically promising results in this animal model went to just show disappointments in clinical trials. Hence, they evidently are an excellent first line of testing, but after, some other animal models, closer to Alzheimer’s should be used. Yes, it means extra time, but it also means products with higher chances of success. The past endless failures of the putative vaccines and monoclonal antibodies after excellent results in mice, has created havoc and confusion in the Alzheimer’s disease research area.

Leave a Comment

Your email address will not be published. Required fields are marked *